Research ties diabetic foot ulcers to higher ESRD costs

04/24/2014 | Renal and Urology News

Data on patients with end-stage renal disease showed those who had diabetic foot ulcers required more erythropoiesis-stimulating agents and had higher monthly inpatient and outpatient costs than those without DFU. The findings were presented at a National Kidney Foundation meeting.

View Full Article in:

Renal and Urology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA